BNT162b2 (B.1.1.7)

**BNT162b2 (B.1.1.7)** is a monovalent mRNA vaccine developed by BioNTech and Pfizer that encodes the full-length SARS-CoV-2 spike protein from the Alpha variant (B.1.1.7 lineage), incorporating mutations that preserve neutralization-sensitive sites. It utilizes lipid nanoparticle (LNP) delivery of nucleoside-modified RNA (modRNA) to induce a robust immune response, including neutralizing antibodies and T-cell activity, primarily against COVID-19 caused by variant strains. Investigated in clinical trials such as BNT162-17 for safety and immunogenicity as a standalone booster or component of multivalent formulations targeting evolving SARS-CoV-2 variants like Delta (B.1.617.2).[1]